Aelan Cell Technologies to Showcase Advances in Next Generation Regenerative Product at 14th Annual Meeting of International Federation for Adipose Therapeutics and Science (IFATS)

SAN FRANCISCO, Nov. 16, 2016 /PRNewswire/ -- Aelan Cell Technologies, Inc. (www.aelanct.com) announced today that Meenakshi Gaur, Ph.D., Director of Stem Cell Program at Aelan, will give a presentation titled "TIME DEPENDENT CHANGE IN THE SECRETION OF BIOLOGICS AND IMMUNOMODULATORY CAPACITY OF AUTOLOGOUS COMBINATION DEVICE" at the 14th Annual Meeting of International Federation for Adipose Therapeutics and Science (IFATS) to be held in San Diego, CA on November 17-20, 2016. The presentation will take place on Friday, November 18th, from 11:20a.m.‐1:00 p.m. PST at the Westin San Diego Gaslamp Quarter as part of the session titled "Basic Research: Inflammation and Fibrosis."

Existing stem cell therapies and those in development have been challenged by efficacy and safety issues, regulatory barriers, high-cost, and limited reimbursement.  Dr. Gaur will describe Aelan's novel type of therapeutic modality, termed Factor Production Unit (FPU). Aelan's novel technology is a combination device for the controlled, versatile and measured production of biologics which has been positioned as a new generation of regenerative therapy products for multiple indications. In systemic application or ex-vivo, FPU is tailored to fulfill the promise of regenerative medicine and improve existing immunotherapies in a personalized, patient–specific manner.

Dr. Gaur will also provide examples of how the technology can be applied in clinics for autoimmune indications and discuss the set of results from a clinical feasibility study indicating that FPU technology can be effectively deployed in allogenic or autologous fashion.

About Aelan Cell Technologies:

Aelan Cell Technologies is a San Francisco-based company engaged in the research, discovery, development and commercialization of innovative biomedical technologies for the advancement of human health and longevity. With a growing intellectual property portfolio of technologies and medical tools, Aelan has assembled an experienced team - bringing together scientific and business expertise - to successfully lead its products through each phase of development.

For more information about Aelan Cell Technologies, please visit: www.aelanct.com     

About  IFATS:   

IFATS is a non-profit scientific society that promotes the exchange of information among researchers.  The Society does not endorse, certify, or otherwise provide recommendations about any specific treatments or practitioners. Membership in the Society does not involve a review of treatments offered by the member. Our Objectives: To bring together as members, professionals of the science, medical and industry areas for productive collaborations around the adipose tissue research in all its possible fields. To create a platform where our members can collaborate actively, discuss, comment and share information which may be directly translated to therapeutic applications. IFATS is currently the world's only interdisciplinary fat tissue society. We are committed to serve as the premier global incubator in the field of fat applied technology. Our Areas of Interest: IFATS current scientific areas of interest relate to facilitating the development of treatments for excess body fat, the generation of new fat tissue for reconstruction after cancer or birth-related defects and the use of adipose tissue as a source of mesenchymal stem cells that have the potential to regenerate and repair different body tissues.

For more information about IFATS, please visit www.ifats.org  

Logo - http://photos.prnewswire.com/prnh/20160720/391695LOGO

SOURCE Aelan Cell Technologies, Inc.